Why the study?
Reperfusion therapy is recommended in acute high-risk pulmonary embolism but reportedly underused, and data on epidemiology, management, and outcomes in Portugal are scarce.
Does reperfusion therapy reduce mortality and MACE in patients with acute high-risk pulmonary embolism compared to no reperfusion?
Population
Consecutive HR-PE patients admitted to a thromboembolic disease referral center (3.8% of 1955 acute PE patients)
Comparison
Reperfusion therapy vs non-reperfusion
Design
Retrospective cohort study
Follow-up
Mean 2.5±3.3 years
Authors
Loading...
Should not yet change practice; leaves open whether PE teams or catheter therapies can safely close the reperfusion gap.
Does reperfusion therapy reduce mortality and MACE in patients with acute high-risk pulmonary embolism compared to no reperfusion?
Reperfusion therapy is underutilized in high-risk pulmonary embolism, primarily due to advanced age and contraindications, but its use is associated with significantly lower short- and long-term mortality.
Martinho et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: